What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Internal medicine, Oncology, Lung cancer, Cancer and Surgery are his primary areas of study.
His study in Clinical trial, Performance status, Randomized controlled trial, Regimen and Clinical endpoint is done as part of Internal medicine.
David R. Gandara interconnects Phases of clinical research, Epidermal growth factor receptor, Pathology, Docetaxel and Radiation therapy in the investigation of issues within Oncology.
His Lung cancer research is multidisciplinary, relying on both Respiratory disease, Chemotherapy, Carboplatin, Carcinoma and Hazard ratio.
His biological study spans a wide range of topics, including Ondansetron and Anesthesia.
His work in Surgery tackles topics such as Placebo which are related to areas like Gastroenterology.
His most cited work include:
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer (2559 citations)
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial (2085 citations)
- Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer (1429 citations)
What are the main themes of his work throughout his whole career to date?
David R. Gandara spends much of his time researching Internal medicine, Oncology, Lung cancer, Chemotherapy and Cancer.
His studies in Internal medicine integrate themes in fields like Gastroenterology and Surgery.
His work carried out in the field of Oncology brings together such families of science as Carboplatin and Carcinoma.
In his study, Pathology is inextricably linked to Cancer research, which falls within the broad field of Lung cancer.
His research integrates issues of Regimen, Radiation therapy and Toxicity in his study of Chemotherapy.
His research links Pharmacology with Cancer.
He most often published in these fields:
- Internal medicine (71.01%)
- Oncology (61.47%)
- Lung cancer (41.75%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (71.01%)
- Oncology (61.47%)
- Lung cancer (41.75%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Oncology, Lung cancer, Cancer research and Atezolizumab.
His work in Docetaxel, Phases of clinical research, Chemotherapy, Clinical endpoint and Clinical trial is related to Internal medicine.
His Oncology research integrates issues from Biomarker, Cancer, Immunotherapy and Lung.
His Lung cancer study combines topics in areas such as Targeted therapy, Carcinoma, Epidermal growth factor receptor and Hazard ratio.
His Cancer research study also includes fields such as
- Exon which is related to area like Osimertinib,
- Circulating tumor DNA which intersects with area such as DNA sequencing.
The concepts of his Atezolizumab study are interwoven with issues in PD-L1, Surgery, Overall survival and Cancer immunotherapy.
Between 2016 and 2021, his most popular works were:
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial (2085 citations)
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. (391 citations)
- Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC (217 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
The scientist’s investigation covers issues in Internal medicine, Oncology, Lung cancer, Atezolizumab and Cancer research.
His research combines Surgery and Internal medicine.
The Oncology study combines topics in areas such as Carboplatin, Clinical endpoint, Phases of clinical research and Confidence interval.
His Lung cancer study incorporates themes from Targeted therapy, Carcinoma, Intensive care medicine and Hazard ratio.
His Atezolizumab research incorporates themes from PD-L1, Randomized controlled trial and Cancer immunotherapy.
David R. Gandara has included themes like Cancer, Somatic evolution in cancer, Mutation, Cyclin-dependent kinase and Exon in his Cancer research study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
